^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ECT204
i
Other names: ECT-204, JWATM 204, JWATM-204, ECT204, JWATM204, ECT 204
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Eureka Therap, JW (Cayman) Therap
Drug class:
γδ TCR modulator, GPC-3 inhibitor
Related drugs:
7ms
ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
P2, N=30, Recruiting, Eureka Therapeutics Inc. | Trial completion date: Dec 2027 --> Dec 2026
Trial completion date • Metastases
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
cyclophosphamide • Stivarga (regorafenib) • ECT204
8ms
ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
P2, N=24, Recruiting, Eureka Therapeutics Inc. | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
Trial completion date • Trial primary completion date • Metastases
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
ECT204
8ms
ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
P2, N=24, Recruiting, Eureka Therapeutics Inc. | Phase classification: P1/2 --> P2
Phase classification • Metastases
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
ECT204
11ms
ARYA3: ECT204 T-Cell Therapy in Adults With Advanced HCC (clinicaltrials.gov)
P1/2, N=24, Recruiting, Eureka Therapeutics Inc. | Trial completion date: Jul 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 | N=12 --> 24
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
ECT204
11ms
A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=20, Recruiting, Shanghai Ming Ju Biotechnology Co., Ltd.
Trial completion date • Trial primary completion date • CAR T-Cell Therapy • Metastases
|
cyclophosphamide • ECT204
almost1year
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P1, N=20, Recruiting, Shanghai Ming Ju Biotechnology Co., Ltd.
New P1 trial • CAR T-Cell Therapy • Metastases
|
cyclophosphamide • ECT204
3years
ARYA3: ECT204 T-Cell Therapy in Adults With Advanced HCC (clinicaltrials.gov)
P1/2, N=12, Recruiting, Eureka Therapeutics Inc. | Initiation date: Aug 2021 --> Dec 2021
Clinical • Trial initiation date
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
ECT204
over3years
ARYA3: ECT204 T-Cell Therapy in Adults With Advanced HCC (clinicaltrials.gov)
P1/2, N=12, Recruiting, Eureka Therapeutics Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
ECT204
over3years
ARYA3: ECT204 T-Cell Therapy in Adults With Advanced HCC (clinicaltrials.gov)
P1/2, N=12, Not yet recruiting, Eureka Therapeutics Inc.
Clinical • New P1/2 trial
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
ECT204
Share via
